NCT03889912 2026-01-21
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Regeneron Pharmaceuticals
Phase 1 Completed
Clinical Trials
14 trialsNCT04272034 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT04925713 2024-08-02
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
TuHURA Biosciences, Inc.
Phase 1 Completed
NCT03646188 2024-03-12
Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
SkinJect, Inc.
Phase 1 Terminated
NCT03775525 2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1 Unknown
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT00880308 2020-12-19
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01208831 2020-12-19
An East Asian Study of LDE225
Novartis
Phase 1 Completed
NCT01106508 2020-12-17
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT03734913 2020-07-22
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT00968981 2017-07-11
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Genentech, Inc.
Phase 1 Completed
NCT02097875 2015-04-21
Safety Study of a Fluorescent Marker to Visualize Cancer Cells
Blaze Bioscience Australia Pty Ltd
Phase 1 Completed
NCT00670189 2014-08-15
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT01204073 2013-07-02
A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies
Millennium Pharmaceuticals, Inc.
Phase 1 Completed